The comorbidity and co-medication profile of patients with progressive supranuclear palsy

Greten, Stephan; Wegner, Florian; Jensen, Ida; Krey, Lea; Rogozinski, Sophia; Fehring, Meret; Heine, Johanne; Doll-Lee, Johanna; Poetter-Nerger, Monika; Zeitzschel, Molly; Hagena, Keno; Pedrosa, David J.; Eggers, Carsten; Buerk, Katrin; Trenkwalder, Claudia; Claus, Inga; Warnecke, Tobias; Suess, Patrick; Winkler, Juergen; Gruber, Doreen; Gandor, Florin; Berg, Daniela; Paschen, Steffen; Classen, Joseph; Pinkhardt, Elmar H.; Kassubek, Jan; Jost, Wolfgang H.; Toenges, Lars; Kuehn, Andrea A.; Schwarz, Johannes; Peters, Oliver; Dashti, Eman; Priller, Josef; Spruth, Eike J.; Krause, Patricia; Spottke, Annika; Schneider, Anja; Beyle, Aline; Kimmich, Okka; Donix, Markus; Haussmann, Robert; Brandt, Moritz; Dinter, Elisabeth; Wiltfang, Jens; Schott, Bjoern H.; Zerr, Inga; Baehr, Mathias; Buerger, Katharina; Janowitz, Daniel; Perneczky, Robert; Rauchmann, Boris-Stephan; Weidinger, Endy; Levin, Johannes; Katzdobler, Sabrina; Duezel, Emrah; Glanz, Wenzel; Teipel, Stefan; Kilimann, Ingo; Prudlo, Johannes; Gasser, Thomas; Brockmann, Kathrin; Hoffmann, Daniel C.; Klockgether, Thomas; Krause, Olaf; Heck, Johannes; Hoeglinger, Guenter U. und Klietz, Martin (2024): The comorbidity and co-medication profile of patients with progressive supranuclear palsy. In: Journal of Neurology, Bd. 271, Nr. 2: S. 782-793

Abstract

BackgroundProgressive supranuclear palsy (PSP) is usually diagnosed in elderly. Currently, little is known about comorbidities and the co-medication in these patients.ObjectivesTo explore the pattern of comorbidities and co-medication in PSP patients according to the known different phenotypes and in comparison with patients without neurodegenerative disease.MethodsCross-sectional data of PSP and patients without neurodegenerative diseases (non-ND) were collected from three German multicenter observational studies (DescribePSP, ProPSP and DANCER). The prevalence of comorbidities according to WHO ICD-10 classification and the prevalence of drugs administered according to WHO ATC system were analyzed. Potential drug-drug interactions were evaluated using AiDKlinik (R).ResultsIn total, 335 PSP and 275 non-ND patients were included in this analysis. The prevalence of diseases of the circulatory and the nervous system was higher in PSP at first level of ICD-10. Dorsopathies, diabetes mellitus, other nutritional deficiencies and polyneuropathies were more frequent in PSP at second level of ICD-10. In particular, the summed prevalence of cardiovascular and cerebrovascular diseases was higher in PSP patients. More drugs were administered in the PSP group leading to a greater percentage of patients with polypharmacy. Accordingly, the prevalence of potential drug-drug interactions was higher in PSP patients, especially severe and moderate interactions.ConclusionsPSP patients possess a characteristic profile of comorbidities, particularly diabetes and cardiovascular diseases. The eminent burden of comorbidities and resulting polypharmacy should be carefully considered when treating PSP patients.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin > Munich Cluster for Systems Neurology (SyNergy)
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• Sprache: Englisch
• DFG: Gefördert durch die Deutsche Forschungsgemeinschaft (DFG) - 390857198